Download CV - Research

Daniel L. Hertz
[email protected]
Campus Address:
911 Oakland Ave. Apt 8
Ann Arbor, MI 48109
Cell Phone: (908) 230-8508
Permanent Address:
304 Roanoke Road
Westfield, NJ 07090
(908) 232-9285
Objective
Career as a prominent independent investigator in collaborative translational oncology research.
Current
Employment
Research Assistant Professor
Department of Clinical, Social, and Administrative Sciences
University of Michigan College of Pharmacy
Education
University of North Carolina At Chapel Hill
UNC Eshelman School of Pharmacy
Division of Pharmacotherapy and Experimental Therapeutics
Chapel Hill, NC 27516
Degree: Doctor of Philosophy (PhD) May 2013
Rutgers, The State University of New Jersey
Ernest Mario School of Pharmacy
Piscataway, NJ 08854
Degree: Doctor of Pharmacy (PharmD) May 2008
GPA: 3.91 / 4.0 Summa Cum Laude
Awards Received
Graduate Education Advancement Board Impact Award 2013
American Association of Cancer Research Scholar-In-Training Award 2012
Cancer Institute of New Jersey Young Philanthropist Award 2011
AFPE Pre-Doctoral Fellowship 2010, competitive renewal 2011
Excellence in Teaching/Instruction Assistance Award 2009
Ernest Mario School of Pharmacy Honors Program Graduate 2008
Cell Biology Achievement Award 2008
Rho Chi-AFPE First Year Graduate Scholarship 2008
Martin Daffner Endowed Scholarship 2007
New Jersey Center For Biomaterials Summer Research Fellowship 2006
John & Josephine Calasibetta Scholarship 2006
Rho Chi National Pharmacy Honor Society Inductee 2006
Novartis-AFPE Gateway to Research Scholarship 2005-2006
Martin Daffner Endowed Scholarship 2005
Pharmacy Alumni Association Scholarship 2005
“Knight In Shining Armor” Award for Student Involvement Spring 2005
Eric D. Seifert Scholarship 2004
IGERT-Summer Undergraduate Research Fellowship 2004
Joseph E. Rood Memorial Award 2002
National Honor Society 2001
Dean’s List: Fall Term 2002-Spring Term 2008
Previous Research
Experience






Scientific
Manuscripts
1. UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental
Therapeutics, Dr. Howard L McLeod, September 2008 to current
Discovery and validation of pharmacogenetic predictors of taxane dose limiting toxicities
Pilot study of rosiglitazone as an in vivo CYP2C8 probe to explain paclitaxel PK variability
Gene expression changes in murine dorsal route ganglia during chemo-induced neuropathy
Correlation of immortalized cell line in vitro sensitivity and in vivo chemotherapy response
2. Ernest Mario School of Pharmacy at Rutgers University, Division of Pharmaceutics and
Drug Delivery, Dr. Patrick J Sinko, September 2004 to May 2007
Creation of mouse breast cancer metastasis model for evaluation of novel biodegradable
hydrogel delivery system for known cytotoxic agents
3. Rutgers University Laboratory of Surface Modification, Dr. Yves Chabal, February 2004
to August 2004
Synthesis and purification of semi-conducting organic layer for use in biocompatible thin film
transistor
1) Hertz DL, McLeod HL, Hoskins JM. Pharmacogenetics of breast cancer therapies (Review).
Breast 2009;18(suppl 3):S59-63
2) Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, et al. Pilot Study of Rosiglitazone as
an in vivo Probe of Paclitaxel Exposure, Br J Clin Pharmacol. 2012 Jul;74(1):197-200
3) Hertz DL, McLeod HL, Irvin WJ, Tamoxifen and CYP2D6: A Contradiction of Data (Review).
The Oncologist 2012;17(5):620-30 (Selected for CME credit)
4) Hertz DL, Dees EC, Motsinger-Reif AA, Drobish A, Winham S, et al. CYP2C8*3 predicts
benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel, Breast Cancer
Res Treat. 2012 Jul;134(1):401-10
5) Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, et al. CYP2C8*3 increases risk of
neuropathy in breast cancer patients treated with paclitaxel, Ann Oncol. 2013
Jun;24(6):1472-8.
6) Krens SD, McLeod HL, Hertz DL, Pharmacogenetics, enzyme probes and therapeutic drug
monitoring as potential tools for individualizing taxane therapy, Pharmacogenomics
2013;14(5):555-574
7) Hertz DL, McLeod HL, Use of Pharmacogenetics for Predicting Cancer Prognosis and
Treatment Exposure, Response and Toxicity, Journal of Human Genetics 2013
Jun;58(6):346-52.
8) Hertz DL, Germline Pharmacogenetics of Paclitaxel for Cancer Treatment,
Pharmacogenomics Journal, (In Press)
9) Sarah McWhinney-Glass*, Stacey J. Winham*, Daniel L. Hertz, Jane Yen Revollo, Jim Paul,
Yijing He, Robert Brown, Alison A. Motsinger-Reif, and Howard L. McLeod for the Scottish
Gynaecological Clinical Trials Group, Cumulative Genetic Risk Predicts Platinum/TaxaneInduced Neurotoxicity, Clinical Cancer Research (In Press)
Grant and
Fellowship Writing
AFPE Pre-Doctoral Fellowship 2010 (funded, competitive renewal 2011)
National Research Service Awards for Individual Postdoctoral Fellows (F32) 2010, (unfunded)
Breast Cancer Research Foundation Renewal 2009-2012 (funded, PI: Dr. Lisa A. Carey)
Rho Chi-AFPE First Year Graduate Scholarship 2008 (funded)
National Science Foundation Graduate Research Fellowship Program 2008 (unfunded)
New Jersey Center For Biomaterials Summer Research Fellowship 2006 (funded)
Novartis-AFPE Gateway to Research Scholarship 2005-2006 (funded)
IGERT-ISURF Undergraduate Research Fellowship Summer 2004 (funded)
Posters and
Presentations
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB
(ALLIANCE) 90401. (Poster Session: Abstract #11053)

American Society of Clinical Oncology June 3, 2013
Patients Carrying CYP2C8*3 are at Increased Risk of Paclitaxel-Induced Neuropathy (Poster
Discussion: PD 10-07)

San Antonio Breast Cancer Symposium Dec 7, 2012
Pharmacogenomics: Translation and Implementation (Presentation)

31st NSGC Annual Education Conference Oct 26, 2012
Integration of Scientific Writing into an Applied Biostatistics and SAS Programming Course for
Pharmaceutical Sciences Graduate Students (Poster: P0-11, Manuscript:
http://analytics.ncsu.edu/sesug/2012/PO-11.pdf)

South East SAS Users Group 2012 Conference Oct 14, 2012
Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy
during paclitaxel treatment (Poster Discussion: Abstract No. 10515)

American Society of Clinical Oncology June 5, 2012
Breast Cancer Patients Carrying the CYP2C8*3 Variant are More Likely to Achieve Clinical
Complete Response from Neoadjuvant Paclitaxel Treatment (Poster Discussion: PD 07-10)

San Antonio Breast Cancer Symposium Dec 11, 2010
Creation of a Murine Mammary Carcinoma Model to Test Metronomic Delivery of a
Chemotherapeutic Agent (presentation)

16th Annual Ernest Mario School of Pharmacy Honors Program Symposium April 26,
2007
Use of a Degradable Hydrogel for Metronomic Delivery of a Chemotherapeutic Agent (poster)

The 8th NJ Symposium on Biomaterials Science November 8-10, 2006
Synthesis of PTTP Semi-Conducting Organic Layer For a Thin Film Transistor (presentation)

IGERT Summer Undergraduate Research Fellowship (ISURF) Symposium August 12,
2004
Journal Reviewer
Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Pharmacogenetics
and Genomics, Molecular Cancer Therapeutics, BMC Medical Genomics, Breast Cancer
Research and Treatment, The Annals of Pharmacotherapy
Teaching
Experience
Quantitative Methods in Clinical Research (DPET 831) Guest Lecturer 2012
 Produced and presented lecture, “Statistics in Pharmacogenetics”
 Created recitation assignment comparing Bonferroni correction with False Discovery Rate
Science and Methods in Drug Development (DPET 841) Course Development Team 2011


Developed syllabus including course description, objectives, and lecture topics
Liaison to adjunct faculty who served as primary lecturers
Quantitative Methods in Clinical Research (DPET 831) Super Teaching Assistant 2010
 Oversaw weekly recitation in which students analyzed a dataset with SAS statistical software
 Introduced and graded new recitation assignment format to mimic scientific manuscript writing
Teaching Assistant for various professional and graduate level courses 2008-2010
 Graded assignments and exams
 Maintained blackboard or sakai course portal
Whizard Academy for Mathematics and English. Mathematics Tutor. July 2007-October 2007
 Strengthen understanding of familiar concepts and facilitate learning of new material
 Evaluate student progress and make recommendations for future work
Busch Learning Center. General and Organic Chemistry Tutor. June 2004- May 2005
 Assisted undergraduate students in understanding chemistry concepts and exam preparation
 Completed certification for Level I & Level II tutor
Professional
Memberships
American Association of Pharmaceutical Scientists: Clinical Pharmacology and Translational
Research Section, 2004-Current
Alliance for Clinical Trials in Oncology (ACTION/CALGB), 2010-Current
American Society of Clinical Oncology (ASCO), 2012-Current
British Pharmacological Society, 2012-Current
Activities
GSO-DPET Division Representative’09-‘11, GPEN 2010 Pharmacogenomics Short Course
Coordinator, Graduate Recruitment Ambassador, Carolina Cancer Focus, Sigma Alpha Pi
National Society of Leadership and Success: Chapter Co-Adviser ’09-‘10, Consilience for
Community Development Planning Team Director, Founder and President of Student Movement
Against Cancer (SMAC) at Rutgers University, High Speed Chase For The Cure Planning Team
’06 -‘08, Mensa Member, “Impact 2004” Leadership Conference Planning Team, Avon Walk for
Breast Cancer 2004 and 2005 Team Leader
Clinical Rotations
and Pharmacy
Externship
Experience
Medical Genetics Clinic, Lineberger Comprehensive Cancer Center at UNC, May-Aug. 2010
 Shadowed Dr. Jim Evans, medical oncologist and genetic counselors
 Produced visual materials on genetics and BRCA to aid discussions with patients
Breast Cancer Clinic, Lineberger Comprehensive Cancer Center at UNC, May-Aug. 2010
 Shadowed Dr. Carey Anders, medical oncologist
 Learned about the role of personalized medicine, such as Oncotype Dx, in clinical care
FDA-Office of Special Health Issues, Rockville, MD, March-April 2008
 Assisted with communication between FDA and general public
 Helped prepare a presentation on the need for uniform clinical trial ID numbers by
attempting to locate each trial mentioned in the labeling of bevacizumab and the
corresponding FDA press release.
Hackensack University Medical Center, Hackensack, NJ, Jan.-Feb. 2008
 Monitored and managed patient therapeutic plans
 Prepared 4 lectures: AML, ALL, MDS, and oncologic pain

Prepared 3 other projects: journal club, drug monograph, investigation into a recurring
medication error
Saiff Drugs, Highland Park, NJ, Nov.-Dec. 2007
 Input and filled new prescriptions and refills
 Analyzed patient profiles to recommend financially optimal Medicare Part D plan
Needham Co., Assistant to Dr. Mark Monane, New York, NY, Oct.-Nov. 2007
 Critiqued and evaluated corporate presentations
 Prepared industry piece on Hsp90 targeting in oncology
Child Health Institute of New Jersey, Pediatric Hematology and Oncology Unit, New Brunswick,
NJ, Sept.-Oct. 2007
 Monitored and managed patient therapeutic plans
 Gave medication recommendations to hospital staff
 Prepared 4 presentations: patient case on stem cell transplantation, neutropenic fever
seminar, sickle cell disease seminar, and literature review of rasburicase vs. allopurinol
Children’s Specialized Hospital, Mountainside, NJ July-Aug. 2007
 Filled and checked medication carts
 Prepared 3 presentations for pharmacy staff: patient case on meningitis, spina bifida
seminar, and examination of the link between vaccines and autism
Ar-Ex Pharmacy, Fords, NJ, May-June 2007
 Input and filled new prescriptions and refills
 Coordinated and oversaw Blood Pressure Health Day
References
Available upon request